Literature DB >> 21860354

Impact of cerebrovascular disease on cognitive function in HIV-infected patients.

Beau K Nakamoto, Victor G Valcour, Kalpana Kallianpur, Chin-Yuan Liang, Aaron McMurtray, Dominic Chow, Erin Kappenburg, Cecilia M Shikuma.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21860354      PMCID： PMC3160604          DOI： 10.1097/QAI.0b013e31821ff8bd

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  9 in total

Review 1.  Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.

Authors:  Justin C McArthur; Joseph Steiner; Ned Sacktor; Avi Nath
Journal:  Ann Neurol       Date:  2010-06       Impact factor: 10.422

2.  HIV proviral DNA associated with decreased neuropsychological function.

Authors:  Bruce Shiramizu; Robert Paul; Andrew Williams; Cecilia Shikuma; Michael Watters; John Grove; Victor Valcour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

3.  Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.

Authors:  Samanta Simioni; Matthias Cavassini; Jean-Marie Annoni; Aline Rimbault Abraham; Isabelle Bourquin; Véronique Schiffer; Alexandra Calmy; Jean-Philippe Chave; Ezio Giacobini; Bernard Hirschel; Renaud A Du Pasquier
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

Authors:  P Vivithanaporn; G Heo; J Gamble; H B Krentz; A Hoke; M J Gill; C Power
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

5.  Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Authors:  E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price
Journal:  Neurology       Date:  2010-08-11       Impact factor: 9.910

Review 6.  Vascular risk factors and dementia: how to move forward?

Authors:  Anand Viswanathan; Walter A Rocca; Christophe Tzourio
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

7.  The impact of HIV-associated neuropsychological impairment on everyday functioning.

Authors:  Robert K Heaton; Thomas D Marcotte; Monica Rivera Mindt; Joseph Sadek; David J Moore; Heather Bentley; J Allen McCutchan; Carla Reicks; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2004-05       Impact factor: 2.892

8.  Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men.

Authors:  J T Becker; L Kingsley; J Mullen; B Cohen; E Martin; E N Miller; A Ragin; N Sacktor; O A Selnes; B R Visscher
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

9.  Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.

Authors:  V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910
  9 in total
  9 in total

1.  Diabetes and cognitive decline in a French cohort of patients infected with HIV-1.

Authors:  Carole Dufouil; Laura Richert; Rodolphe Thiébaut; Mathias Bruyand; Hélène Amieva; Frédéric-Antoine Dauchy; Jean-François Dartigues; Didier Neau; Philippe Morlat; Patrick Dehail; François Dabis; Fabrice Bonnet; Geneviève Chêne
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

2.  White matter hyperintensities correlate to cognition and fiber tract integrity in older adults with HIV.

Authors:  Christa Watson; Edgar Busovaca; Jessica M Foley; I Elaine Allen; Christopher G Schwarz; Neda Jahanshad; Talia M Nir; Pardis Esmaeili-Firidouni; Benedetta Milanini; Howard Rosen; Owen T Carmichael; Paul M Thompson; Victor G Valcour
Journal:  J Neurovirol       Date:  2017-01-18       Impact factor: 2.643

3.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

Review 4.  Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Belinda Cruse; Lucette A Cysique; Romesh Markus; Bruce J Brew
Journal:  J Neurovirol       Date:  2012-04-14       Impact factor: 2.643

5.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

6.  Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals.

Authors:  Beau K Nakamoto; Neda Jahanshad; Aaron McMurtray; Kalpana J Kallianpur; Dominic C Chow; Victor G Valcour; Robert H Paul; Liron Marotz; Paul M Thompson; Cecilia M Shikuma
Journal:  J Neurovirol       Date:  2012-05-15       Impact factor: 2.643

7.  HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria.

Authors:  Lai Gwen Chan; Nagaendran Kandiah; Arlene Chua
Journal:  BMJ Open       Date:  2012-02-13       Impact factor: 2.692

8.  HCV, but not HIV, is a risk factor for cerebral small vessel disease.

Authors:  Susan Morgello; Jacinta Murray; Sarah Van Der Elst; Desiree Byrd
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-09-04

9.  Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era.

Authors:  Isaac H Solomon; Umberto De Girolami; Sukrutha Chettimada; Vikas Misra; Elyse J Singer; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2017-02-17       Impact factor: 3.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.